FATE - CIK 0001434316
FATE THERAPEUTICS INC (FATE) reported revenue of $6.65M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $6.65M | -51.2% |
| FY 2024 | $13.63M | -78.5% |
| FY 2023 | $63.53M | -34.0% |
| FY 2022 | $96.30M | +72.4% |
| FY 2021 | $55.85M | +77.7% |
| FY 2020 | $31.43M | +194.3% |
| FY 2019 | $10.68M | +125.3% |
| FY 2018 | $4.74M | +15.4% |
| FY 2017 |
FATE THERAPEUTICS INC (FATE) reported revenue of $6.65M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, FATE THERAPEUTICS INC's revenue grew from $1.17M to $6.65M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.11M |
| -6.7% |
| FY 2016 | $4.40M | +81.1% |
| FY 2015 | $2.43M | +150.4% |
| FY 2013 | $971.00K | -63.6% |
| FY 2012 | $2.67M | +128.2% |
| FY 2011 | $1.17M | - |